EA201100626A1 - Лечение рака с помощью ионизирующего облучения и иммуноцитокинов - Google Patents

Лечение рака с помощью ионизирующего облучения и иммуноцитокинов

Info

Publication number
EA201100626A1
EA201100626A1 EA201100626A EA201100626A EA201100626A1 EA 201100626 A1 EA201100626 A1 EA 201100626A1 EA 201100626 A EA201100626 A EA 201100626A EA 201100626 A EA201100626 A EA 201100626A EA 201100626 A1 EA201100626 A1 EA 201100626A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immunocytokins
cancer
help
treatment
ionizing radiation
Prior art date
Application number
EA201100626A
Other languages
English (en)
Russian (ru)
Inventor
Томас Уикхем
Ульрике Гнад-Фогт
Штефан Г. Клинц
Силвиа А. Холден
Карл Йозеф Каллен
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201100626A1 publication Critical patent/EA201100626A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/208IL-12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EA201100626A 2008-10-21 2009-10-21 Лечение рака с помощью ионизирующего облучения и иммуноцитокинов EA201100626A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10714608P 2008-10-21 2008-10-21
PCT/EP2009/007533 WO2010046097A1 (en) 2008-10-21 2009-10-21 Cancer treatments with radiation and immunocytokines

Publications (1)

Publication Number Publication Date
EA201100626A1 true EA201100626A1 (ru) 2011-12-30

Family

ID=41510762

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100626A EA201100626A1 (ru) 2008-10-21 2009-10-21 Лечение рака с помощью ионизирующего облучения и иммуноцитокинов

Country Status (12)

Country Link
US (1) US20100330029A1 (https=)
EP (1) EP2337579A1 (https=)
JP (1) JP2012506394A (https=)
KR (1) KR20110086101A (https=)
CN (1) CN102196815A (https=)
AU (1) AU2009306711A1 (https=)
BR (1) BRPI0919857A2 (https=)
CA (1) CA2741130A1 (https=)
EA (1) EA201100626A1 (https=)
MX (1) MX2011004193A (https=)
WO (1) WO2010046097A1 (https=)
ZA (1) ZA201103726B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX387323B (es) * 2014-02-19 2025-03-18 Merck Patent Gmbh Il-12 dirigida al cáncer en combinación con il-7 para usarse en el tratamiento de cáncer.
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US9861833B1 (en) * 2017-03-30 2018-01-09 Norman H. Anderson Methods of treating melanoma
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
CN112768029B (zh) * 2020-12-27 2023-10-13 上海市东方医院(同济大学附属东方医院) 一种基于单细胞测序的组合用药推荐设备、方法及介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020110538A1 (en) * 1999-12-28 2002-08-15 Health Research, Inc. Methods and products for tumor immunotherapy using cytokines
KR20030064275A (ko) * 2000-06-29 2003-07-31 메르크 파텐트 게엠베하 면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
DK1454138T3 (da) * 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
CA2593648A1 (en) * 2005-01-10 2006-07-13 Research Development Foundation Targeted chimeric molecules for cancer therapy
PL1966238T3 (pl) * 2005-12-30 2012-09-28 Merck Patent Gmbh Warianty interleukiny-12p40 o polepszonej stabilności

Also Published As

Publication number Publication date
AU2009306711A1 (en) 2010-04-29
CA2741130A1 (en) 2010-04-29
EP2337579A1 (en) 2011-06-29
JP2012506394A (ja) 2012-03-15
WO2010046097A1 (en) 2010-04-29
ZA201103726B (en) 2012-01-25
BRPI0919857A2 (pt) 2015-12-15
US20100330029A1 (en) 2010-12-30
KR20110086101A (ko) 2011-07-27
MX2011004193A (es) 2011-05-24
CN102196815A (zh) 2011-09-21

Similar Documents

Publication Publication Date Title
EA201100626A1 (ru) Лечение рака с помощью ионизирующего облучения и иммуноцитокинов
CY1123258T1 (el) Μεθοδος θεραπειας για τον καρκινο
EA200970915A1 (ru) Способы лечения с использованием гликопэгилированного g-csf
MX2020009773A (es) Terapia de combinacion.
SG10201902664RA (en) Combination therapy for treating cancer
CY1115782T1 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
MXPA05011656A (es) Combinaciones para el tratamiento de enfermedades que implican proliferacion, migracion o apoptosis celulares de celulas de mieloma, o angiogenesis.
WO2011146777A3 (en) Device and method for providing a synergistic combination of phototherapy and a non-light energy modality to the brain
PH12015502260B1 (en) C. novyi for the treatment of solid tumors in humans
MX2020001727A (es) Terapia de combinacion.
UA86586C2 (ru) Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
EA201001853A1 (ru) Фармацевтическая комбинация
PH12021551276A1 (en) Combination therapy for the treatment of cancer
MX2025008270A (es) Uso prolongado de docetaxel en el tratamiento del cáncer.
EA202192964A1 (ru) Комбинированная терапия
MX2021001764A (es) Terapia de combinacion.
MX393477B (es) Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas.
NZ760040A (en) Methods of treating brain tumors using combination therapy
BR112022001796A2 (pt) Tratamento focal do câncer de próstata
MX2024006078A (es) Metodo para tratar el cancer con acilfulveno y radiacion.
ATE442188T1 (de) Bestrahlungseinrichtung
TW200724158A (en) Combination therapy in the treatment of cancer
EA202190294A1 (ru) Комбинированная терапия для лечения рака
MX2021001084A (es) Terapia de combinacion para el tratamiento del cancer.